Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo- controlled trial

Bonderup, O. K.; Hansen, J. B.; Teglbjærg, P. S.; Christensen, L. A.; Fallingborg, J. F.
January 2009
Gut;Jan2009, Vol. 58 Issue 1, p68
Academic Journal
Objective: To evaluate the efficacy and safety of long- term budesonide therapy for the maintenance of clinical remission in patients with collagenous colitis. Design: Randomised, placebo-controlled study with a 24- week, blinded follow-up period without any treatment. Setting: Three gastroenterology clinics in Denmark. Patients: Forty-two patients with histologically confirmed collagenous colitis and diarrhoea (more than three stools! day). Interventions: Patients in clinical remission after 6 weeks' open-label therapy with oral budesonide (Entocort CIR capsules, 9 mg/day) received 24 weeks' double-blind maintenance therapy with budesonide 6 mgI day or placebo. Thereafter, patients entered the 24-week, blinded follow-up period. Main Outcome Measure: The proportion of patients in clinical remission (three or fewer stools/day) at the end of maintenance therapy. Findings: A total of 34 patients in remission at week 6 were randomly assigned to budesonide 6 mg/day (n = 17) or placebo (n = 17). After 24 weeks' maintenance treatment, the proportions of patients in clinical remission were 76.5% (13 of 17) with budesonide and 12% (2 of 17) with placebo (p<0.001). At 48 weeks (the end of the follow-up period, without any treatment) these values were 23.5% (4 of 17) and 12% (2 of 17), respectively (p = 0.6). The median times to relapse after stopping active treatment (6 plus 24 weeks in the budesonide group; 6 weeks in the placebo group) were 39 and 38 days, respectively. Long-term treatment with budesonide was well tolerated. Conclusions: Long-term maintenance therapy with oral budesonide is efficacious and well tolerated for preventing relapse in patients with collagenous colitis. The risk of relapse after 24 weeks' maintenance treatment is similar to that observed after 6 weeks' induction therapy.


Related Articles

  • Is the exclusion of children under 24 months from anthelmintic treatment justifiable? Montresor, Antonio; Stoltzfus, Rebecca J.; Albonico, Marco; Tielsch, James M.; Rice, Amy L.; Chwaya, Hababu M.; Savioli, Lorenzo // Transactions of the Royal Society of Tropical Medicine & Hygiene;Mar2002, Vol. 96 Issue 2, p197 

    There are no reports documenting toxicity or adverse effects after treatment of children aged < 24 months with benzimidazole derivatives and there is an urgent need to clarify this point in light of the potential detrimental effect that soil-transmitted helminthiasis has on this age-group. A...

  • A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea. Drakoularakou, A.; Tzortzis, G.; Rastall, R. A.; Gibson, G. R. // European Journal of Clinical Nutrition;Feb2010, Vol. 64 Issue 2, p146 

    Background/Objectives:Prebiotics have attracted interest for their ability to positively affect the colonic microbiota composition, thus increasing resistance to infection and diarrhoeal disease. This study assessed the effectiveness of a prebiotic galacto-oligosaccharide mixture (B-GOS) on the...

  • Bismuth Subsalicylate in the Treatment of Chronic Diarrhea of Childhood. Gryboski, Joyce D.; Hillemeier, Craig; Grill, Bruce; Kocoshis, Samuel // American Journal of Gastroenterology;Nov1985, Vol. 80 Issue 11, p871 

    Twenty-nine infants and children, age 2-70 months with chronic diarrhea, were admitted to a double-blind, parallel clinical trial. The subjects were randomly assigned to receive either a bismuth subsalicylate liquid or a placebo liquid formulation. Treatment was given for 7 days with dosage...

  • Risk Factors for Extended Duration of Acute Diarrhea in Young Children. Strand, Tor A.; Sharma, Pushpa R.; Gjessing, Håkon K.; Ulak, Manjeswori; Chandyo, Ram K.; Adhikari, Ramesh K.; Sommerfelt, Halvor // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Objective and Background: We sought to identify predictors of extended duration of diarrhea in young children, which contributes substantially to the nearly 1 1/2 million annual diarrheal deaths globally. Methods: We followed 6-35 month old Nepalese children enrolled in the placebo-arm of a...

  • Post-Diarrhea Chronic Intestinal Symptoms and Irritable Bowel Syndrome in North American Travelers to Mexico. Okhuysen, Pablo C.; Jiang, Zhi Dong; Carlin, Lily; Forbes, Charles; DuPont, Herbert L. // American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1774 

    OBJECTIVES: Irritable bowel syndrome (IBS) has been reported to complicate bacterial diarrhea. Because of the frequency of international travel and the common occurrence of bacterial diarrhea, we studied the occurrence of chronic gastrointestinal complaints and post-diarrhea IBS in North U.S....

  • Neurogastroenterology/motility free papers.  // Gut;Apr2005 Supplement 2, Vol. 54, pA18 

    The article presents information on abstracts related to neurogastroenterology. According to an abstract cilansetron is efficacious in relieving bowel habit related symptoms in irritable bowel syndrome with diarrhoea predominance. Diarrhoea and abdominal pain/discomfort are key symptoms of...

  • Review: Saccharomyces boulardii reduces risk for antibiotic-associated diarrhea.  // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p45 

    This article presents a study which reveals that Saccharomyces boulardii reduces risk for antibiotic-associated diarrhea. Randomized controlled trials (RCTs) were conducted which compared S. boulardii with placebo or no additional intervention in adults and children who received antibiotics for...

  • Safety Profile of Tegaserod, a 5-HT4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome. Hasler, William L.; Schoenfeld, Philip // Drug Safety;2004, Vol. 27 Issue 9, p619 

    This article reviews the safety and tolerability profile of tegaserod, a novel selective partial agonist of the serotonin 5-HT4 receptor. Tegaserod was recently approved for the treatment of women with irritable bowel syndrome (IBS) with constipation. Tegaserod exhibits rapid absorption from the...

  • A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. Chang, Lin; Ameen, Vanessa Z.; Dukes, George E.; McSorley, David J.; Carter, Eric G.; Mayer, Emeran A. // American Journal of Gastroenterology;Jan2005, Vol. 100 Issue 1, p115 

    BACKGROUND: A randomized, double blind, placebo-controlled dose-ranging study was conducted to assess the efficacy of alosetron in men with diarrhea-predominant irritable bowel syndrome (IBS).METHODS: Six hundred and sixty-two men were randomized to treatment with alosetron 0.5, 1.0, 2.0, 4.0...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics